CF PharmTech gets $90 million in latest financing round for inhaled drug development

CF PharmTech, which says it is developing a variety of OINDPs, announced that it has closed a Series E financing round  that will be used to support development of its pipeline products. The $90 million round was led by Shanghai-based New Alliance Capital.

In August 2017, the company said that it had raised $65 million in a Series D round to support development of its own products and for expansion of its CDMO services.

New Alliance Capital Executive Director Lei Cai commented, “New Alliance Capital prioritizes investment opportunities in the healthcare industries. Respiratory treatments and inhaled medications, in particular, are promising because of the high technological barriers to entry and immense potential for growth. CF PharmTech has worked meticulously to build strong technological platforms that support the development of a comprehensive range of products. The integrity and professionalism of the core team at CF PharmTech impressed us deeply.”

CR-CP Life Science Fund Managing Director Da Liu said, “CF PharmTech is one of China’s most innovative and pioneering pharmaceutical companies to focus on respiratory disease treatments. As a pharma company, CF PharmTech fully embodies a commitment to quality and global standards. As one of the few leading private pharmaceutical companies of respiratory drug delivery, CF PharmTech has immense potential for growth.”

Read the CF PharmTech press release.